SilkTears
Maple Grove
About SilkTears
Developing the world's first protein containing eye drop that both comforts the eye immediately and provides ongoing relief of dry eye symptoms.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $3.6M
- Funding stage: Seed
- Last round: Seed (Sep 2023)
- Website: silktears.com
- Phone: [email protected]
Industries & Categories
Biopharma, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/silktears-74945 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.